Evidence map›Paper›PMID 40635009›Full record

ArticleGut pathogens2025

Profiling of the tumor-associated microbiome in patients with hepatocellular carcinoma.

Christian Schulz, Ramiro Vilchez-Vargas, Elif Öcal, Nadine Koch, Daniel Puhr-Westerheide, Lu Fornés Burnell, Heidrun Hirner-Eppeneder, Julia Benckert, Maciej Pech, Peter Reimer and 6 more

Abstract read
In one paragraph

Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Christian SchulzDepartment of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
Ramiro Vilchez-VargasDepartment of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
Elif ÖcalDepartment of Radiology, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Nadine KochDepartment of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
Daniel Puhr-WesterheideDepartment of Radiology, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Lu Fornés BurnellDepartment of Radiology, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Heidrun Hirner-EppenederDepartment of Radiology, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Julia BenckertDepartment of Hepatology and Gastroenterology, Charité, Berlin, Germany.
Maciej PechDepartments of Radiology and Nuclear Medicine, Otto-Von-Guericke University of Magdeburg, Magdeburg, Germany.
Peter ReimerDepartment of Radiology, Karlsruhe Hospital, Karlsruhe, Germany.
Chris VerslypeDepartment of Hepatology and Digestive Oncology, University Hospital Gasthuisberg, Leuven, Belgium.
Christiane KuhlDepartment of Diagnostic and Interventional Radiology, University Hospital, RWTH Aachen University, Aachen, Germany.
Albert TranDepartment of Immunology, Université De Nice Sophia-Antipolis, CHU De Nice, Nice, France.
Jens RickeDepartment of Radiology, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Peter MalfertheinerDepartment of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
Marianna Alunni-FabbroniDepartment of Radiology, LMU University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. marianna.alunni@med.uni-muenchen.de.ORCID https://orcid.org/0000-0002-9710-1662

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor tissues have been shown to host a diverse array of bacteria, suggesting a link between the intratumoral microbiota and the development and progression of cancer. The aim of this explorative study was to perform microbiome analysis in liver tumor and to evaluate its relationship with cancer stage and survival outcome.

resultsWe conducted an exploratory study on a cohort of 20 hepatocellular cancer patients from the SORAMIC trial. Patients were divided into curative and palliative groups according to treatment type (local ablation, alone or combined with systemic therapy). The V1-V2 regions of 16 S rRNA were sequenced starting from archival tissues. Amplicon Sequence Variants (ASVs) were taxonomically assigned to the upper (UGI) or lower (LGI) gastrointestinal tract. Bacteria were identified in both tumoral and non-tumoral tissues, showing higher diversity and correlation between diversity and shorter survival in the palliative group (S. aureus p < 0.05; B. parvula p < 0.01; A. chinensis p < 0.01). Both therapy groups were enriched with the genus Bacilli, including Streptococcus spp., Gemella haemolysans and Helicobacter pylori, commonly found in UGI. The results suggested that among palliative patients and those with shorter survival, G. haemolysans was more prevalent, while H. pylori was more often found in curative patients with longer survival. However none of the results were significantly different (p > 0.05). A higher microbiome biodiversity was associated with an increased number of lesions (Hoylesella, Agathobacter, Sphingobium, Cardiobacterium, Photobacterium and Serratia, all with p < 0.01).

conclusionsThe presence of bacteria, predominantly from communities of the UGI, suggests their translocation into liver tissue due to impaired barrier function of the upper gut or the ascending pathway along the biliary duct system. The intratumoral prevalence of bacteria with proinflammatory and oncogenic potential suggests their potential role in HCC pathomechanisms.

Indexed as

Helicobacter pyloriHepatocellular carcinomaInterventional radiologyLiverMicrobiota

Identifiers

PMID40635009
PMCPMC12243435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.